Asian patients with non-cystic fibrosis bronchiectasis had a lower annualized exacerbation rate and less lung function ...
MedPage Today on MSN
Could This Be the First Disease-Modifying Drug in Bronchiectasis?
C HICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic ...
New York, USA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight Insmed’s BRINSUPRI (brensocatib) has ...
The use of CT scans is moving beyond a simple diagnostic tool for non–cystic fibrosis bronchiectasis to become a practical ...
The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the brand name Brinsupri. File Photo by John Angelillo/UPI For the first ...
Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...
If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic ...
Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Non-Cystic Fibrosis Bronchiectasis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has ...
The Key Non-Cystic Fibrosis Bronchiectasis Companies in the market include - Boehringer Ingelheim, Zambon, Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback